Derek J. Jonker

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

K. Gelmon, L. Seymour, J. Lyons, 2013, Investigational New Drugs.

Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression.

D. Jonker, G. Goss, J. Maroun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.